The listing of Fuyuan pharmaceutical is imminent: the net amount raised will reach 1.6 billion yuan, and hubaifan is the actual controller

6 month 26 Sunday night , Beijing Fuyuan Pharmaceutical Co., Ltd （ Hereinafter referred to as “ Fuyuan medicine ”,SH:601089） Release 《 Announcement on the issuance results of Fuyuan pharmaceutical's initial public offering 》. according to the understanding of , Fuyuan medicine plans to be listed on the main board of Shanghai Stock Exchange , It is expected to be listed in the near future .

Announcement shows that , Fuyuan Pharmaceutical Co., Ltd. has 415546 Shares have not been subscribed by investors , Among them, the number of online investors giving up subscription is 412108 stocks , The waived subscription amount is 602.5 Ten thousand yuan ; Offline investors give up the number of subscriptions 3438 stocks , The waived subscription amount is 5.0 Ten thousand yuan .

among , Investors who give up their subscription include Yabang Investment Holding Group Co., Ltd （ abbreviation “ Yabang Group ”） etc. , The number of subscription waivers is 382 stocks . According to BeiDuo finance and Economics , Yabang Group is A Yabang shares, a listed company （SH:603188） The controlling shareholder of .

Earlier announcements showed that , The stock issuance price of Fuyuan pharmaceutical is 14.62 element / stocks , The number of issues is 12000 Thousands of stocks , All for public issuance of new shares . On this basis , The total amount of funds raised by Fuyuan pharmaceutical is 17.54 One hundred million yuan , The net amount raised is 16.36 One hundred million yuan , For production and construction projects 、 Innovative drugs and generic drugs R & D and R & D center construction projects .

Public information display , Fuyuan medicine was established in 1999 year 2 month , On 2019 In, it was changed into a joint stock company . According to the prospectus , Fuyuan medicine is mainly engaged in the research and development of pharmaceutical preparations and medical devices 、 Production and marketing , The products have strong competitiveness and high market recognition .

at present , The pharmaceutical preparations of Fuyuan medicine mainly cover the cardiovascular system 、 Chronic kidney disease 、 Dermatosis 、 Digestive system 、 Diabetes mellitus 、 Mental nervous system 、 Gynecology and other fields , Products include losartan potassium hydrochlorothiazide tablets 、 Olmesartan axetil tablets 、 Telmisartan Tablets 、 Losartan potassium hydrochlorothiazide tablets and olmesartan kamedoxomil tablets 、 Kaiselu, etc ; The business of medical devices mainly focuses on humidification and oxygen absorption devices , The main products include disposable oxygen tubes, etc .

As of the signing date of the prospectus , Fuyuan pharmaceutical paroxetine hydrochloride tablets 、 Olmesartan axetil tablets 、 Montelukast sodium chewable tablets 、 Trimetazidine hydrochloride tablets 、 Gliclazide Sustained release tablets 、 Repaglinide tablets 、 Telmisartan Tablets 、 Venlafaxine hydrochloride sustained release capsules, etc 8 Varieties have won the bid to purchase with quantity .

As of the end of the reporting period , Fuyuan medicine has the authorized patent 282 term , Among them, invention patents 87 term ; Fuyuan medicine said in the prospectus , Its products under development are rich , As of the signing date of the prospectus, the projects under development of generic pharmaceutical preparations 23 individual 、 Innovative drugs under development 5 individual 、 Medical devices under research 4 individual .

Financial aspects , Fuyuan medicine 2019 year 、2020 Years and 2021 The annual income is 24.25 One hundred million yuan 、25.35 Million dollars 28.38 One hundred million yuan , Net profit is 2.20 One hundred million yuan 、2.65 Million dollars 3.20 One hundred million yuan , The net profits after deduction of non profits are 2.00 One hundred million yuan 、2.51 Million dollars 3.05 One hundred million yuan .

During the reporting period , The income of Fuyuan medicine is mainly contributed by pharmaceutical preparations , Among the chemicals that generate revenue, chemical generic drugs are mainly used .2019 year 、2020 Years and 2021 year , The corresponding sales revenue of generic drug products is respectively 21.47 One hundred million yuan 、22.61 Million dollars 25.81 One hundred million yuan , The proportion in the operating income of the company is respectively 88.55%、89.18% and 90.97%.

2022 year 1-3 month （ first quarter ）, The operating income of Fuyuan pharmaceutical is 7.48 One hundred million yuan , a 2021 In the same period of 6.11 One hundred million yuan growth 22.43%; Net profit 8599.39 Ten thousand yuan , a 2021 In the same period of 5937.53 Ten thousand yuan growth 44.83%; The net profit attributable to the parent after deduction is 7965.66 Ten thousand yuan , a 2021 In the same period of 5856.27 Ten thousand yuan growth 36.02%.

Fuyuan medicine said in the prospectus , The company expects that 2022 year 1-6 month （ In the first half of the year ） The operating income of is 15 One hundred million yuan to 17 One hundred million yuan , Year-on-year growth 13.43%-28.55%; Net income of 1.9 One hundred million yuan to 2.3 One hundred million yuan , Year-on-year growth 13.93%-37.92%; Net profit after deduction is 1.81 One hundred million yuan to 2.22 One hundred million yuan , Year-on-year growth 12.00%-37.37%.

In the equity structure before this listing , The number of shares of Fuyuan medicine held by XinHeCheng holdings is 176,316,354 stocks , The proportion in the total share capital of the company is about 48.98%, Is the controlling shareholder of the company . among , Hubaifan, director of Fuyuan pharmaceutical, indirectly controls the company through XinHeCheng holding and qinjin investment 76.29% Shares of , Is the actual controller of the company .

by comparison , Chairman of Fuyuan Pharmaceutical 、 Huanghe, the general manager, indirectly holds shares through Huakang Taifeng 19.51%.